General information on Anti-RBD-2 antibody
The SARS-CoV-2 spike protein receptor-binding domain (RBD) is the most important target for the development of new therapies for COVID-19. The development of antibodies that can target that specific area can be done in vivo, which is a lengthy or in vitro process that can take advantage of the flexibility of display technologies, such as pH age display.
The anti-CoV-RBD antibody was developed by pHa to display the extensive library of COVID-19 antibodies (LiAb-SFCOVID-19 ™) against SARS-CoV-2 RBD. Considering that the generation of antibodies by pH age does not require animal immunization or the use of immunogenic antigens, only small RBD proteins are used to isolate specific RBD ligands from the LiAb-SFCOVID-19 TM library. In addition, as the library is composed of immune libraries from patients with COVID-19, it has the largest important biological antibodies with important neutralizing activities.
Therefore, this specific antibody is a fully human immunoglobulin in IgG format. Enzyme-linked immunosorbent assay (ELISA) was used to test and verify its affinity for recombinantly expressed RBD. In addition, the neutralizing activity was tested by the Alternative Virus Neutralization Test SARS-CoV-2 (sVNT), which was designed to quickly assess the potential for neutralizing new antibodies without using natural virus particles.
Finally, IgG antibodies are expressed in the XtenCHO ™ high-performance transient mammalian system, and show very stable stability and consistently produce high yields.
There are no reviews yet.